Insmed Incorporated (BST:IM8N)

Market Cap	17.68B +65.5%
Revenue (ttm)	710.81M +115.1%
Net Income	-1.03B
EPS	-4.95
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	81.07
Previous Close	81.60
Day's Range	80.12 - 83.44
52-Week Range	61.50 - 184.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 6, 2026

About Insmed

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1988
• Employees: 1,664
• Stock Exchange: Stuttgart Stock Exchange
• Ticker Symbol: IM8N

Financial Performance

In 2025, Insmed's revenue was $606.42 million, an increase of 66.73% compared to the previous year's $363.71 million. Losses were -$1.28 billion, 39.7% more than in 2024.

Financial numbers in USD